Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
Macular telangiectasia type 2 (MacTel) is a rare, progressive retinal disease characterized by neurodegenerative changes, localized retinal degeneration, and alterations in the retinal vasculature. It usually presents bilaterally and leads to gradual central vision loss, and its early signs and symptoms are subtle and nonspecific. In this program, expert faculty discuss recent innovations in approved therapy for this condition and opportunities for early detection and diagnosis.
This educational activity is an archive of the live virtual symposium held on August 2, 2025.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and other eye care professionals who treat patients with MacTel.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of anti-VEGF intravitreal injection therapies in the management of MacTel
- Evaluate emerging evidence supporting the use of novel therapies in the management of MacTel
- Integrate current evidence-based interventions for MacTel into clinical practice to optimize disease outcomes
- Apply advanced diagnostic and therapeutic interventions to the management of MacTel
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here